Is bone-marrow microinvolvement in non-small cell lung cancer a reliable indicator of tumour recurrence and prognosis?
Our results show that bone-marrow microinvolvement is not unusual, and its occurrence cannot be translated into early tumour recurrence or poor outcome during an intermediate-term follow-up, which means bone-marrow microinvolvement may be an epiphenomenon rather than true metastasis in NSCLC.
The GST can be terminated at 150 minutes without sacrificing sensitivity. A GH peak at a time other than 90 or 120 minutes may be a new important indicator of GH deficiency.